Table 2.
Baseline characteristics of pooled cohort across quartiles of galectin-3
| Participant characteristics | Galectin-3 quartiles (ng/ml) |
|||
|---|---|---|---|---|
| <9.04 | 9.04−12.65 | 12.66− 16.76 | >16.76 | |
| n | 211 | 210 | 210 | 210 |
| Cohort | ||||
| SKS | 54 (26) | 78 (37) | 85 (41) | 63 (30) |
| C-PROBE | 157 (74) | 132 (63) | 125 (60) | 147 (70) |
| Age, yr | 52 (16) | 58 (15) | 59 (15) | 60 (14) |
| Male | 126 (60) | 131 (62) | 108 (51) | 100 (48) |
| Race | ||||
| White | 124 (59) | 109 (52) | 125 (60) | 106 (51) |
| Black | 65 (31) | 79 (38) | 65 (31) | 80 (38) |
| Other | 22 (10) | 22 (11) | 19 (9) | 23 (11) |
| Education | ||||
| <High school | 17 (9) | 16 (8) | 22 (11) | 28 (14) |
| Completed high school | 100 (50) | 117 (57) | 115 (56) | 112 (55) |
| Completed college or more | 84 (42) | 72 (35) | 67 (33) | 62 (31) |
| Current smoker | 23 (11) | 25 (12) | 33 (16) | 25 (12) |
| Prevalent CVD | 63 (30) | 74 (35) | 71 (34) | 95 (45) |
| Prevalent heart failure | 23 (11) | 33 (16) | 24 (11) | 38 (18) |
| Prevalent CAD | 43 (20) | 50 (24) | 53 (25) | 61 (29) |
| Statin use | 65 (31) | 85 (41) | 99 (47) | 104 (50) |
| Diabetes | 65 (31) | 83 (40) | 92 (44) | 114 (54) |
| Hypertension | 165 (78) | 183 (87) | 184 (88) | 192 (91) |
| Antihypertensive use | 157 (74) | 164 (78) | 177 (84) | 188 (90) |
| SBP, mm Hg | 129 (17) | 132 (20) | 132 (19) | 135 (22) |
| DBP, mm Hg | 74 (11) | 76 (12) | 75 (12) | 74 (12) |
| BMI, kg/m2 | 30.1 (7.3) | 31.7 (7.7) | 31.1 (7.2) | 33.9 (8.8) |
| eGFR, ml/min per 1.73 m2 | 65 (30) | 53 (24) | 45 (24) | 39 (25) |
| UACR, mg/g | 93 [11−601] | 93 [13−366] | 230 [15−934] | 329 [42−1186] |
BMI, body mass index; C-PROBE, Clinical Phenotyping and Resource Biobank; CAD, coronary artery disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; SKS, Seattle Kidney Study; UACR, urine albumin-to-creatinine ratio.
Data are N (%) or [interquartile range].